The trial included more than 1,000 patients to assess the efficacy and safety of a 4-mg dose of baricitinib plus remdesivir versus remdesivir in hospitalized patients with COVID-19. Baricitinib in combination with remdesivir met the primary endpoint of reduction of time to recovery in comparison with remdesivir.
The companies said study investigators noted an approximately one-day reduction in median recovery time for the overall patient population treated with COVID-19 in combination with remdesivir versus those treated with remdesivir. They also noted that the finding is statistically significant.
Price: 148.09, Change: +1.87, Percent Change: +1.28
|Significant Insider Sales Reported in Shares of KalV...|
|Insider Sale at Mastercard (MA) Continues Selling Trend|
|Insider Selling at Illumina (ILMN) Continues with Si...|
|Insider Selling in Salesforce.com (CRM) Shares Conti...|
|VeriSign (VRSN) sees Significant Insider Sales Exten...|